Further to the announcement made by Shire plc on January 8, 2019, Shire today announces that, following an application by Shire, the UK Listing Authority has cancelled the listing of Shire Shares on the premium listing segment of the Official List and the London Stock Exchange has cancelled the trading of Shire Shares on the London Stock Exchange’ s main market...
January 8, 2019– Shire plc. Notification of transactions by persons discharging managerial responsibilities. For further information please contact:.
RNS Number: 5418 M Citigroup Derivatives Markets Inc 08 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 5266 M Goldman Sachs& Co. LLC 08 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS. Rule 8.5 of the Takeover Code.
RNS Number: 5253 M J.P. Morgan Securities LLC 08 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. On May 8, 2018, Shire plc and Takeda Pharmaceutical Company Limited announced that they had reached agreement on the terms of a recommended cash and share...
January 7, 2019– Shire plc. For further information please contact:. Shire is the global biotechnology leader serving patients with rare diseases and specialized conditions.
RNS Number: 4164 M Citigroup Global Markets Inc. 07 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY. A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE. Rule 8.3 of the Takeover Code.
RNS Number: 4008 M Citigroup Derivatives Markets Inc 07 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 3811 M J.P. Morgan Securities LLC 07 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 3749 M Nomura International PLC 07 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2795 M Citigroup Global Markets Inc. 04 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2776 M Citigroup Derivatives Markets Inc 04 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 2472 M J.P. Morgan Securities LLC 04 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 1553 M Citigroup Derivatives Markets Inc 03 January 2019. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
RNS Number: 1442 M Takeda Pharmaceutical Company Ltd 03 January 2019. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Osaka, Japan- January 3, 2019- Takeda Pharmaceutical Company Limited notes Shire plc's...
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION. Applications have been made for the suspension of trading in Shire Shares on the London Stock Exchange's main market for listed securities and the...
RNS Number: 1299 M J.P. Morgan Securities LLC 03 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN.
RNS Number: 1274 M Nomura International PLC 03 January 2019 FORM 8.5. PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN. EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY STATUS.
Shire Plc
SHP.L
Shire Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    917.10M

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist